40 results about "Fibronectins" patented technology

The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The present invention produces a large number of mesenchymal stem cells in a short time in a culture medium containing no heterologous components by including a step of culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

The invention belongs to the technical field of biomedical treatment, and particularly relates to recombinant human fibronectin max-rhFN as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin mat-rhFN is as shown in SEQ ID NO. 2. The molecular weight of the recombinant human fibronectin mat-rhFN provided by the invention is about 130kDa, the purity is higher than 95%, and the endotoxin content is relatively low. Through cell biology detection, the recombinant human fibronectin mat-rhFN provided by the invention is good in activity, has the effects of promoting cell proliferation and cell adhesion, and also has a good protection effect in a keratinocyte anti-SDS stimulation test, and meanwhile, the recombinant human fibronectin mat-rhFN provided by the invention has a remarkable interaction with collagen.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

The invention relates to the technical field of protein engineering, particularly discloses a human-like fibronectin and a skin filling composition thereof, and provides a recombinant human-like fibronectin, the amino acid sequence of which is as shown in SEQ ID No.1, and the recombinant human-like fibronectin can promote adhesion or migration of skin fibroblasts, so that the human-like fibronectin can be used as a skin filling composition. And the lasting stability of the molecular structure can be maintained in subcutaneous tissues. The skin filling composition containing the recombinant human-like fibronectin can provide supporting and filling functions through subcutaneous injection, so that the purpose of correcting wrinkles is achieved.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

The invention discloses a high-performance tissue sealant as well as a preparation method and application thereof, and relates to the technical field of medical materials. The tissue sealant is prepared from the following raw materials: amino-containing protein, a multi-arm polyethylene glycol derivative and an optional multi-amino polymer, wherein the amino-containing protein comprises at least one of lactoferrin, phycocyanin, whey protein, beta-lactoglobulin, cytochrome C, recombinant collagen, recombinant fibronectin and alpha-lactalbumin. The sealant provided by the invention has the characteristics of rapid gelling, strong adhesion, high mechanical strength, low swelling, antibacterial property and the like, can realize efficient tissue wound sealing, hemostasis and repair in a wet complex environment, is simple and convenient to prepare, safe in material source and good in biocompatibility, is suitable for being used in various wound scenes, and has wide application prospects. Good application prospects are realized.

The application discloses a double-domain recombinant humanized fibronectin, the sequence of which is shown as SEQ ID NO. 3, which is composed of the collagen binding domain and the cell binding domain of human fibronectin. The application also provides a recombinant expression vector and a host cell containing the gene coding the protein. The protein is efficiently expressed by eukaryotic cells and engineered Escherichia coli, and a fermentation and purification process suitable for industrial scale is established. Functional experiments prove that, compared with the single-domain commercial fibronectin product, the double-domain recombinant humanized fibronectin of the application can significantly promote the proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, beauty and skin care and biomedical materials.

Provided are a recombinant human fibronectin (FN) having a complex function of soothing, a preparation method therefor, and the use thereof. Said recombinant human fibronectin has an amino acid sequence shown as SEQ ID NO.1. By adding a hyaluronic acid interaction segment of human fibronectin while retaining main segments of human fibronectin cell adhesion and integrin receptor interaction, and linking the two domains by means of a flexible "linker" amino acid sequence GGS, the recombinant human FN protein having the complex function is constructed. While possessing core characteristics of traditional recombinant fibronectins, the present recombinant human fibronectin also exhibits an effect of soothing cell irritations. Therefore, the prepared recombinant human fibronectin is expected to exhibit a good effect in soothing skin irritation in the field of functional active skincare products.

The invention belongs to the technical field of daily skin care products, and relates to a biological agent with a bionic ECM structure and application of the biological agent in the field of skin aging resistance. The biological agent with a bionic ECM structure is prepared by simulating components of natural ECM of skin and mainly comprises fibronectin rh FN-LN, collagen, glycoprotein, serum albumin, a polyamino acid polysaccharide condensation compound, mannitol, trehalose and auxiliary materials. The auxiliary materials comprise elastin, decapeptide-4 and the like. An elastinase inhibition ratio test and a human skin fibroblast proliferation test prove that the biological agent with the bionic ECM structure has the effects of repairing, resisting aging and improving skin compactness.

The invention provides a human fibronectin-collagen recombinant fusion protein for lip care. The fusion protein structurally comprises a fibronectin part, a connecting peptide and a collagen part, wherein the amino acid sequence of the fibronectin part is as shown in SEQ ID NO. 1, and the amino acid sequence of the collagen part is as shown in SEQ ID NO. 2. Functional regions of human fibronectin and human III-type collagen are specifically intercepted, and the fibronectin and the collagen are connected through the connecting peptide, so that the high-stability compound protein is obtained, the expression quantity can reach 11.40 g / L, cell adhesion and cell proliferation can be promoted, and the human III-type collagen can be used for preparing the high-stability compound protein. The lip care product has the effects of moisturizing, repairing, nourishing, brightening the skin color of the lips and the skin color around the lips, improving the softness of the lips, fading cheilogramma, improving the gloss around the lips, improving the darkness around the lips and improving the fullness of the lips, and can be used as a raw material of a skin care product.

The invention discloses a fibronectin-based bioactive fragment and application thereof. The amino acid sequence of the bioactive fragment is shown as SEQ ID NO: 1, 2 or 3. The invention also relates to a nucleotide sequence (as shown in SEQ ID NO: 4, 5 or 6) for coding the fragment, a recombinant expression vector containing the nucleotide and a host cell. According to the application of the obtained bioactive fragment in culture of primary mesenchymal stromal cells (MSCs), the fragment can significantly improve the adherence efficiency and proliferation rate of the MSCs, effectively solves the technical problems of difficult in-vitro culture, slow amplification speed and easy differentiation of the MSCs, provides a new tool for large-scale production of high-quality MSCs, and has wide application prospects. Wide application prospects are realized in the fields of tissue engineering and regenerative medicine.

The application belongs to the technical field of biology, and particularly relates to a recombinant fibronectin as well as a preparation method and application thereof. The preparation method of the recombinant fibronectin provided by the application comprises the following steps: constructing a recombinant plasmid containing an optimized nucleotide sequence (SEQ ID NO. 2), transforming Escherichia coli and inducing expression; after the bacterial body is resuspended by a buffer and homogenized by high pressure, alkaline protease is added for one-step enzymolysis, and after inactivation, the precipitate is obtained by centrifugation, washed by NaCl and dissolved by acetic acid, so that a recombinant fibronectin stock solution is obtained, and the amino acid sequence of the recombinant fibronectin (rhFNb) is shown as SEQ ID NO. 1. The preparation method provided by the application does not need chromatography purification, and the refining of the recombinant fibronectin can be completed within 15 minutes, so that the production cycle is effectively shortened while the product purity is ensured to be greater than or equal to 95% and the adhesion activity is high.

The application discloses a fibronectin and collagen fusion protein and a preparation method thereof, the amino acid sequence of the fusion protein is shown as SEQ.ID.NO.4, the fused collagen can effectively reduce the cytotoxicity of the fibronectin and improve the biological safety of raw materials under the premise of not affecting the efficacy of the fibronectin; compared with the original single sequence, the fusion protein can effectively improve the cell proliferation rate of the fibronectin; the fusion with the collagen also obviously increases the expression amount of the fibronectin, and the expression amount can reach 2g / L, which is much higher than the expression amount of the original single sequence; at the same time, the stability of the fibronectin at-20 DEG C, 4 DEG C and 40 DEG C is much higher than the stability of the original single sequence.

The application discloses a kind of recombinant human fibronectin and its preparation method and application, it is related to bioengineering technical field;The amino acid sequence of recombinant human fibronectin prepared in the application is as shown in SEQ ID NO.1, nucleotide sequence SEQ ID NO.2 is shown, synthesis recombination plasmid, the synthesized recombination plasmid is used as template, and PCR amplification is carried out, and PCR amplification product is recovered;Linearization enzyme cutting product is connected with PCR amplification product, and is transformed into escherichia coli competent cell, and linearization expression plasmid is extracted, and linearization expression plasmid is introduced into GS115 competent cell and is transformed, and after screening, induction expression is carried out, and target protein is obtained;The prepared recombinant human fibronectin can be used to promote wound healing.

The invention relates to a phosphorus-containing dendrimer co-loaded fibronectin / melatonin nano-drug as well as a preparation method and application thereof. The nano-drug comprises a phosphorus-containing dendrimer ZY-135 at a hydroxyl terminal, fibronectin FN and melatonin MT. The nano-drug provided by the invention can penetrate through a blood brain barrier, accurately target a diseased region, cooperatively regulate and control microglial cells, nerve cells and vascular endothelial cells, and can realize combined treatment of oxidative stress and inflammation level alleviation, neuroprotection and vascular regeneration of cerebral arterial thrombosis, so that nerve cell apoptosis is reduced, and cerebral arterial thrombosis is reduced. Good clinical transformation prospects and application values are realized.

The invention discloses a fusion protein containing a fibroblast growth factor and fibronectin and application of the fusion protein. The fusion protein comprises a fibronectin truncated fragment (such as FNIIIC or FNIIICFC) and a basic fibroblast growth factor (bFGF). The invention also provides a polynucleotide for coding the fusion protein, a recombinant expression vector and a host cell containing the polynucleotide, and a method for purifying the fusion protein through fermentation culture and affinity chromatography. Experiments show that compared with a single component or FN-full, the fusion protein, especially FNIIICFC-b, disclosed by the invention can remarkably promote proliferation and migration of mesenchymal stem cells (MSC) and up-regulate expression of beneficial factors such as HGF (Hepatocyte Growth Factor) and VEGF (Vascular Endothelial Growth Factor). The fusion protein, the pharmaceutical composition containing the fusion protein and the cell culture coating material containing the fusion protein have wide application prospects in the fields of tissue engineering, regenerative medicine and the like.

The application relates to a chimeric antigen receptor that directly and / or indirectly targets cells and their uses in tumor immunotherapy. The application also relates to polynucleotides that encode the chimeric antigen receptor and optionally accessory genes, vectors, and host cells comprising the chimeric antigen receptor and optionally a second antigen targeting moiety (e.g., a second chimeric antigen receptor or a bispecific molecule). The application also relates to methods for preparing host cells comprising the chimeric antigen receptor and optionally the second antigen targeting moiety.

A method of assessing drug cardiac safety using human stem cell-derived cardiomyocytes, includes: step (A) of preparing cardiomyocytes by culturing human stem cells to differentiate into cardiomyocytes; step (B) of diluting fibronectin in DPBS (Dulbecco's phosphate buffered saline) at a concentration of 50 μg / ml; step (C) of adding the fibronectin solution, obtained by diluting to the concentration of 50 μg / ml in step (B); step (D) of placing the MEA plate; step (E) of removing the fibronectin solution from specific wells of the MEA plate; step (F) of adding a predetermined medium to the specific wells of the MEA plate; and step (G) of measuring changes in information values about beat rate, spike amplitude and field potential duration depending on whether a drug to be assessed has been added to the wells of the MEA plate.

The invention discloses a high-activity recombinant human fibronectin truncation and application thereof.The recombinant human fibronectin truncation provided by the invention has the effects of enhancing the cell adherence capacity and improving the cell proliferation efficiency and virus transfection, is derived from human natural protein, can be applied to MSC cell culture, is a safe and effective biomedical material and has good application prospects. The recombinant human fibronectin truncated body solves the problems that in the prior art, full-length fibronectin cannot be subjected to soluble expression and is insufficient in production performance, and in addition, the recombinant human fibronectin truncated body is subjected to soluble expression, high in expression, good in stability, easy to prepare and capable of being better applied and popularized.

The application provides a hydrogel prepared by cross-linking of methacrylated cross-linking monomers containing functionalized cells; the surface of the functionalized cells is coated with a first coating layer and a second coating layer; the first coating layer is an aminoated positive high molecular material or a fibronectin coating layer; the second coating layer is a 4-amine-2,2,6,6-tetramethylpiperidyl modified high molecular material coating layer; or the surface of the functionalized cells is grafted with 4-amine-2,2,6,6-tetramethylpiperidyl. The functional high molecular material grafted with 4-amine-2,2,6,6-tetramethylpiperidyl is coated on the surface of cells through electrostatic adsorption or layer-by-layer self-assembly with other high molecular materials, and the coated cells are planted into the hydrogel cross-linked by free radical chain reaction for three-dimensional culture of the cells, the polymerization of the cross-linking reaction of the hydrogel is blocked, and the microenvironment of the tissue engineering scaffold around the cells is micro-regulated.

The invention discloses recombinant human fibronectin and related products and application thereof, brand new recombinant human fibronectin FN4, FN5, FN6, FN7 and FN8 are provided for the field, the corresponding amino acid sequences of the recombinant human fibronectin FN4, FN5, FN6, FN7 and FN8 are shown as SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 respectively, and the recombinant human fibronectin can effectively promote cell adhesion, promote cell proliferation and enhance virus transfection efficiency, has high biological activity, and can be used for preparing recombinant human fibronectin. The method can be applied to preparation of related drugs, skin care products, cosmetics, cell culture reagents and cell therapy drugs, and has good practical application value in the fields of medicine, skin care, beauty and the like.

The invention discloses recombinant human fibronectin as well as a preparation method and application thereof, and relates to the technical field of bioengineering. The amino acid sequence of the prepared recombinant human fibronectin is shown as SEQ ID NO.1, and the nucleotide sequence of the recombinant human fibronectin is shown as SEQ ID NO.2. The preparation method comprises the following steps: synthesizing recombinant plasmids, taking the synthesized recombinant plasmids as a template, carrying out PCR (Polymerase Chain Reaction) amplification, and recovering a PCR amplification product; connecting the linearized enzyme digestion product with the PCR amplification product, transforming into escherichia coli competent cells, extracting linearized expression plasmids, introducing the linearized expression plasmids into GS115 competent cells, transforming, screening, and performing induced expression to obtain target protein; the prepared recombinant human fibronectin can be used for promoting wound healing.

The application discloses high-purity chicken plasma fibronectin and a preparation method thereof. The method comprises the following steps: taking fresh chicken plasma as raw material, adding ammonium sulfate to a saturation degree of 20% at low temperature to realize targeted extraction and enrichment of fibronectin; then, a gelatin affinity chromatography column is prepared through gelatin-cyanogen bromide (CNBr) activation gel coupling, specific binding of fibronectin and gelatin is utilized to realize efficient capture and preliminary purification, and gradient arginine solution is adopted to realize impurity washing and elution; finally, high-purity and high-activity fibronectin is obtained through desalination of dextran gel G25 chromatography. Through optimization of the combination process of ammonium sulfate precipitation, specific affinity chromatography and gel filtration, the problems of low purity, easy damage of activity, low efficiency and high cost in the traditional method are solved, the purpose of high-value preparation of high-purity fibronectin from by-product chicken blood is realized. The purity can reach 92.93%, and the high-purity chicken plasma fibronectin can be applied to the fields of biomedicine, cosmetics and cell culture.